Board of Directors

Vanessa Malier

Vanessa Malier is Managing Partner at Kurma Partners, Paris. She joined in September 2013 from Ipsen. Vanessa has over 15 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development.

At Ipsen, Vanessa was VP R&D strategic planning and previously was R&D and commercial lead for Adenuric (febuxostat), successfully approved by CHMP and launched in 2008. Vanessa is a Molecular Biologist and Immunologist by training and started her career at CDC-Innovation (VC group of now BPI).

Olivier Danos, PhD

Olivier Danos is the Senior Vice President and Chief Scientific Officer for REGENXBIO. Prior to joining REGENXBIO, Olivier was Senior Vice President, Cell and Gene Therapy at Biogen Inc.

Olivier was co-founder of Lysogene, a NAV Technology Licensee focused on the development of gene therapy product candidates. He has also served as Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals, Director of the Gene Therapy Consortium of the University College of London, Scientific Director at Genethon, and Senior Director of Research at Somatix Therapy Corporation. Olivier has directed gene therapy research at the Necker - Enfants Malades Hospital in Paris, the French National Centre for Scientific Research, and the Pasteur Institute in Paris.

Anja Harmeier, PhD

Anja Harmeier is Partner at Pureos Bioventures, Zurich. She joined in 2020 from Roche where she held various positions in R&D and was Investment Director at the Roche Venture Fund and has more than 15 years of experience as a scientist, entrepreneur, drug developer and investor. Anja is a Neuroscientist and Biochemist by training with a PhD from the Freie Universit├Ąt Berlin and an MBA from ie Madrid.

Richard Porter, PhD

Richard Porter brings over 20 years of experience working across multiple therapeutic areas in the pharmaceutical and biotech industries.

Prior to joining Corlieve, Richard was the COO of Therachon until the acquisition by Pfizer. Previously he was at Roche in positions of increasing responsibility, most recently as the Global Head of Scientific Business Strategy and Operations Management for Neuroscience Ophthalmology and Rare Diseases directing the strategic and operational activities of the department. He has also served as a Product General Manager of the Emerging Business Unit at Shire Pharmaceuticals, and held scientific leadership positions at Vernalis and ASTRA. Richard received his academic training at the University of Southampton, the University of Oxford (United Kingdom) and at the University of Rochester (United States).